Please use this identifier to cite or link to this item:
|Title:||Development of HIV-1 fusion inhibitors targeting gp41||Authors:||Lu, K.
Asyifah, M. R.
|Keywords:||DRNTU::Science::Medicine::Biomedical engineering||Issue Date:||2014||Source:||Lu, K., Asyifah, M., Shao, F., & Zhang, D. (2014). Development of HIV-1 Fusion Inhibitors Targeting gp41. Current Medicinal Chemistry, 21(17), 1976-1996.||Series/Report no.:||Current medicinal chemistry||Abstract:||The HIV-1 envelope protein glycoprotein 41 (gp41) is crucial in the HIV-1 infection process, therefore gp41 has emerged as an attractive target for drug design against AIDS. During the past few decades, tremendous efforts have been made on developing inhibitors that can prevent the HIV-1 entry process via suppressing functional gp41. In this review, the development of HIV-1 fusion inhibitors targeting gp41 including peptide inhibitors, small molecule inhibitors, vaccines and neutralized antibodies will be discussed.||URI:||https://hdl.handle.net/10356/99957
|ISSN:||0929-8673||DOI:||http://dx.doi.org/10.2174/0929867321666131218094559||Rights:||© 2014 Bentham Science Publishers.||Fulltext Permission:||none||Fulltext Availability:||No Fulltext|
|Appears in Collections:||SPMS Journal Articles|
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.